ARCHIVES

ODAC Rejects Amsacrine NDA, Renews Idarubicin

This article is from The Cancer Letter archive.

Vol. 16 No. 35 | September 14, 1990

Download PDF Visit The Full Archive

Related Articles

Denosumab Demonstrates Superiority Over Zometa For Bone Metastases

August 28, 2009

In Brief: Fischinger Hints of “New Player” At FCRF; Gigliotti Named Cancer Control Science Director

December 12, 1986

UCSF Wins $500,000 Grant From Bristol-Myers Squibb Foundation

March 15, 2002

IOM Committee Advises DOD To Fund Grants; Training, Infrastrucure In Breast Cancer; Goals To Raise Number of New Investigators

May 21, 1993

NCI Faces Major Cuts On Gramm-Rudman Sequestration; Grants, Centers, Trials Slashed

November 3, 1989

The Cancer Letter Takes Summer Publication Break.

August 2, 2002